Publicação científica trimestral do CREMERJ - número 4 - 2022

43 Med. Ciên. e Arte , Rio de Janeiro, v.1, n.4, p.31-44, out-dez 2022 Nefrotoxicidade – Aspectos Básicos Caroline Azevedo Martins e Mauricio Younes-Ibrahim 13. Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness of therapeutic drug monitoring: a systemic review. Ther Drug Monit. 2005; 27:10–17 DOI: 10.1097/00007691-200502000-00004 14. Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009 Mar;24(1):1-10. doi: 10.3904/kjim.2009.24.1.1. 15. Yılmaz Ç and Özcengiz G. Antibiotics: Pharmacokinetics, toxicity, resistance and multidrug efflux pumps. Biochemical pharmacology, 2017;1;133:43-62. DOI: 10.1016/j.bcp.2016.10.005 16. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813–8. DOI: 10.1001/jama.294.7.813. 17. Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41(8):1411–23. DOI: 10.1007/s00134-015-3934-7. 18. Moffett BS, Goldstein SL. Acute kidney injury and increasing nephrotoxic-medication exposure in noncritically-ill children. Clin J American Soc Nephrol. 2011;6(4):856–63. DOI: 10.2215/CJN.08110910. 19. Fux CA, Simcock M, Wolbers M, et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther. 2007;12(8):1165–73. PMID: 18240857. 20. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. Aids. 2009;23(6):689–96. DOI: 10.1097/ QAD.0b013e3283262a64.  21. Uetrechet J, Naisbitt JD. Idiosyncratic Adverse Drug Reactions: Current Concepts. Pharmacol Rev. 2013 Apr; 65(2): 779–808. DOI: 10.1124/pr.113.007450. 22. Schentag JJ, Cerra FB, Plaut ME. Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients. Antimicrob Agents Chemother. 1982;21(5):721–6. DOI: 10.1128/ AAC.21.5.721.  23. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case– control study. BMC Nephrol. 2013; 14:150(1-7). DOI: 10.1186/1471-2369-14-150.  24. Antoniou T, Macdonald EM, Hollands S, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open. 2015;3(2): E166–71. DOI: 10.9778/ cmajo.20140074. 25. Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case–control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86(4):837–44. DOI: 10.1038/ ki.2014.74. 26. Winter MA, Guhr KN, Berg GM. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Pharmacotherapy. 2012;32(7):604–12. DOI: 10.1002/j.1875-9114.2012.01098.x.  27. Levey AS, Titan SM, Powe NR, et al.  Kidney Disease, Race, and GFR Estimation. Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1203-1212. doi: 10.2215/CJN.12791019. 28. Smythe M, Hoffman J, Kizy K, Dmuchowski C. Estimating creatinine clearance in elderly patients with low serum creatinine concentrations. Am J Hosp Pharm. 1994;51(2):198–204. PMID: 8160670. 29. Fu N, Li X, Yang S, et al. Risk score for the prediction of contrast-induced nephropathy in elderly patients undergoing percutaneous coronary intervention. Angiology. 2013;64(3):188-94. DOI: 10.1177/0003319712467224.  30. Gao YM, Li D, Cheng H, Chen YP. Derivation and validation of a risk score for contrast-induced nephropathy after cardiac catheterization in Chinese patients. Clin Exp Nephrol. 2014;8(6):892-8. DOI: 10.1007/s10157-014-0942-9 31. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393–98. DOI: 10.1016/j.jacc.2004.06.068